Brevan Howard Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Brevan Howard Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.12M	Sell	7,930 -18,270	-70%	-$4.27M	0.02%	696
2026 Q1	$5.97M	Sell	26,200 -22,060	-46%	-$4.95M	0.05%	200
2025 Q4	$10.2M	Buy	+48,260	New	+$9.97M	0.11%	118

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Brevan Howard Capital Management's ASND Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Ascendis Pharma A/S (ASND) stake by 70% in Q2 2026, selling an estimated $4.27M and leaving 7,930 shares worth $2.12M. The position accounts for 0.02% of the portfolio, ranked #696.

Brevan Howard Capital Management first reported a position in ASND in Q4 2025 and has held it in 3 quarters since. The position peaked at $10.2M in Q4 2025. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Brevan Howard Capital Management held 7,930 shares of Ascendis Pharma A/S worth $2.12M as of Q2 2026.
Brevan Howard Capital Management sold 18,270 Ascendis Pharma A/S shares in Q2 2026, an estimated $4.27M.
Ascendis Pharma A/S made up 0.02% of Brevan Howard Capital Management's portfolio in Q2 2026, its #696 holding.
Brevan Howard Capital Management first reported a position in Ascendis Pharma A/S in Q4 2025 and has held it in 3 quarters since.
Brevan Howard Capital Management's Ascendis Pharma A/S position peaked at $10.2M in Q4 2025.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.